Loading…

IRadimed Corp.IRMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.

Momentum neutral 43
Mkt cap
$1.05B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$11.1M
20-day average traded
Fwd P/E
34.3×
forward earnings
ROIC−WACC
+43.2 pp
WACC 9.6%
Hurdle
-3 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · USD$82.31
1D-1.4%
1W-4.9%
1M-6.7%
3M-5.0%
6M-8.9%
YTD-15.4%
1Y-3.6%
ATR %3.4%
Beta0.73
52w lowhigh23.7% off high

What IRadimed does

Maker of MRI-compatible IV infusion pumps and patient monitoring systems used during MRI procedures.

Sells the pump system to hospitals and gets recurring revenue from single-use IV sets used with every pump, so the installed base of pumps matters. Its pumps are designed to work inside the magnetic field of an MRI scanner, where ordinary electric pumps cannot be used.

Products and services

  • MRI-compatible IV infusion pumps
  • MRI-compatible patient monitors

Customers

  • Hospitals/imaging centers
  • Radiology departments

Where it sits in the supply chain

  • Medical devices
  • MRI-compatible patient care equipment
  • IV infusion pumps & vital-sign monitors…

What could go right

  • MRI procedure volume growth
  • Hospital replacement of legacy pumps for safety compliance

What could go wrong

  • Small niche/total addressable market
  • Hospital capex cyclicality

Moat: narrow (IP / patents, regulatory licence). One of few makers of infusion pumps safe to use inside the MRI's magnetic field, a narrow regulated niche.

Headquarters: Winter Springs, Florida · Founded: 1992 · Employees: 166

Named competitors

IRadimed at a glance

Size IRadimed (IRMD) is a United States Health Care company (Medical Specialties) with a market value of $1.05B, the 2199th largest of 3,085 United States companies the cockpit tracks. Shares closed at $82.31 on 18 Nov 2026.

Performance Over six months the shares fell 8.9%, against -6.8% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 11.0% over the last twelve months (peer median +10.0%); the operating margin is 32.3% (peer median 11.8%).

Valuation It trades at 34.3× forward earnings against a peer median of 18.4× (2nd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 43.2 points above its cost of capital (9.6% WACC).

Short interest Short interest is 4.6% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 92IRMD 88
Six months, rebased to 100: IRadimed against the median of its 20 peers (local-currency closes).

IRadimed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$89.3M$83.8M$73.2M$65.6M$53.3M
Revenue growth—+14%+12%+23%—
Gross profit$67.5M$64.3M$56.3M$50.2M$41.3M
EBITDA$30.5M$27.3M$22.8M$20.8M$16.3M
Net income$24.0M$22.5M$19.2M$17.2M$12.8M
Free cash flow$26.1M$17.2M$17.6M$6.02M$9.22M
Capital expenditure$1.54M$8.42M$8.82M$8.01M$1.87M
Total debt$0$0$154,688$2.04M$2.21M

Quarterly statements and history in the cockpit →

IRadimed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%SIBN688622301101CSTLEUZIART2141506000553010216523ATEC300685300206DRTSCBLL3001433004066881617730IRMD6-month return →1-month return →
Up and to the right = strong over both horizons. IRadimed is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×301101EUZIART2141506523ATEC3006853002063001433004066881617730IRMDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IRadimed is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%301101CSTLEUZIART2141503010216523300685300206300143688161IRMDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IRadimed is the large dot.

IRadimed competitors and peer comparison

Head to head with its named competitors (IRMD vs MDT vs PHIA.AS vs GEHC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
IRadimed IRMD$1.05B-9%+11%32%34.3×18.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Koninklijke Philips PHIA.AS$29.0B+17%-1%10%16.4×5.9%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%

How IRadimed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IRadimed against its 20 peers (data as of 18 Nov 2026)
MeasureIRMDPeer medianRank in peer set
1-month return-6.7%-5.1%10th lowest of 21
6-month return-8.9%-6.8%10th lowest of 20
Distance from 52-week high-23.7%-29.4%6th highest of 21
Revenue growth (TTM)+11.0%+10.0%9th highest of 19
Operating margin32.3%11.8%5th highest of 20
Forward P/E34.3×18.4×2nd most expensive of 13
Growth the price implies (Req g, 7 yrs)18.5%6.9%3rd most demanding of 14
Growth delivered (Del g)+21.5%+9.9%3rd highest of 14
Hurdle (Req g minus delivered)-3.0 pp-2.2 pp7th least demanding of 14
ROIC minus cost of capital+43.2 pp+1.5 pphighest of 19
EV / EBITDA32.4×8.7×most expensive of 8
Net debt / EBITDA-2.1×0.2×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%

Questions

Who are IRadimed's main competitors?
Named competitors: Medtronic (MDT), Philips (PHIA.AS), GE HealthCare (GEHC). The cockpit's measured peer set (industry) also includes SI-BONE (SIBN), Guangzhou Hexin Instrument (688622.SS), Mingyue Optical Lens (301101.SZ), Castle Biosciences (CSTL), Eckert & Ziegler (EUZ.DE), Integra LifeSciences (IART).
Is IRadimed expensive compared with its peers?
On forward p/e it trades at 34.3× against a peer median of 18.4×, 2nd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has IRadimed stock performed?
Over six months to 18 Nov 2026 the shares returned -8.9% against -6.8% for the median peer; over one year -3.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.